How to Buy Spyre Therapeutics Stock
Spyre Therapeutics Inc
Spyre Therapeutics, Inc. , a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
Spyre Therapeutics stock last closed at $34.25, up 2.87% from the previous day, and has increased 740.49% in one year. It has overperformed other stocks in the Biotechnology industry by 7.64 percentage points. Spyre Therapeutics stock is currently +1,187.59% from its 52-week low of $2.66, and -28.6% from its 52-week high of $47.97.
At the moment, there are 36.15M SYRE shares outstanding. The market capitalization of SYRE is $1.24B. In the last 24 hours, 201,520 SYRE shares were traded.
How to Buy Spyre Therapeutics Stock
Wondering how to invest in Spyre Therapeutics stock? Here's how.
- Choose where to buy Spyre Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Spyre Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Pick your method of payment and add your info.
- Analyze Spyre Therapeutics stock: The Spyre Therapeutics ticker symbol is SYRE. Is Spyre Therapeutics stock a good investment? Should you buy shares of SYRE? How do SYRE's underlying business fundamentals look? Do top analysts think Spyre Therapeutics is a good buy? Why has SYRE's stock price moved recently? (Hint: Our stock market research tools can help you decide if SYRE is a good stock to buy).
- Make your SYRE buy order: Decide if you will purchase SYRE shares at the current market price or use a limit order to buy SYRE shares at a given price.
- Get notifications regarding your SYRE position: Create a watchlist to important updates regarding your new investment in Spyre Therapeutics shares.
Step 1: Choose where to buy Spyre Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy SYRE shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to Shanghai — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal info so you are able to buy SYRE today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create a new brokerage account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have filled out your info on the best free stock trading app, you need to deposit funds:
Watch the tutorial below to see the process of transferring funds into your brokerage account.
Step 4: Analyze Spyre Therapeutics stock
Once you have decided on the best place to buy Spyre Therapeutics stock, it's crucial to research their stock before you buy, so you truly understand the risk as well as the opportunity.
Spyre Therapeutics stock at a glance
SYRE Zen Score
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on SYRE's stock page.
Is SYRE stock overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge SYRE's fair value.
Using relative valuations measures:
- SYRE could be overvalued based on its P/B ratio of 6.73x, relative to Biotechnology industry P/B ratio of 5.93x
You can access additional valuation research on SYRE's stock here.
A look at SYRE Cashflows and Balance Sheet
Pros:
- SYRE has a low debt to equity ratio of 0.4.
- SYRE has $339.60M in cash and short term investments. This is sufficient to cover its annual cash burn of $99.44M.
- There are more short-term assets than long-term liabilities on the SYRE balance sheet.
- There are more short-term assets than short-term liabilities on the SYRE balance sheet.
- SYRE has cash burn of 99435000. It has sufficient cash and short-term investments to cover this for at least one year.
Cons:
- Total SYRE debt is higher than 5 years ago, relative to shareholder equity.
- SYRE profit margin has gone down from -3,598.8% to -38,238.1% in the past year.
Do analysts think it's a good time to buy Spyre Therapeutics stock
Out of 4 Equities analysts who give forecasts on SYRE, the consensus analyst rating on Spyre Therapeutics is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Spyre Therapeutics stock forecast page.
Metrics for Advanced SYRE Traders
SYRE Performance Metrics
Last year, SYRE revenue was $886.00k. In the past five year, SYRE's revenue has increased by -25.61% per year. This was slower than the Biotechnology industry average of 28.88%.
Dive into SYRE's earnings and revenue performance here.
Latest Insiders Trades at SYRE
Over the past year, executives and large shareholders at SYRE have bought more shares than they have sold.
Cameron Turtle, Chief Executive Officer of SYRE, was the latest SYRE insider to buy. They bought $3,928.00 worth of SYRE stock on Feb 15, 2024.
Dig into more about who owns SYRE shares here.
Does SYRE provide a stable income stream?
No, Spyre Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about SYRE
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your SYRE buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, place a limit order.
Hit the Open Trade button and your broker will place the order.
If you want additional help buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your SYRE position
Now that you own some shares in SYRE, you'll want to stay up-to-date on your new company.
Create a watchlist to monitor your SYRE stock.
SYRE Feed
How to Buy Stock in Spyre Therapeutics
To summarize, here are the 6 steps for buying Spyre Therapeutics stock:
- Choose where to buy Spyre Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Analyze Spyre Therapeutics stock
- Make your SYRE buy order
- Get notifications regarding your SYRE position
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Spyre Therapeutics, click the button below.
Other Stock Buying Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.